Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?

Doyle KP, Buckwalter MS.

Brain Behav Immun. 2016 Aug 13. pii: S0889-1591(16)30366-X. doi: 10.1016/j.bbi.2016.08.009. [Epub ahead of print] Review.

PMID:
27531189
2.

Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.

Amory CF, Levine SR, Brey RL, Gebregziabher M, Tuhrim S, Tilley BC, Simpson AC, Sacco RL, Mohr JP; APASS-WARSS Collaborators..

Cerebrovasc Dis. 2015;40(5-6):293-300. doi: 10.1159/000441362.

3.

Thrombolytic therapy at systemic lupus onset with secondary antiphospholipid syndrome. A rare stroke experience.

Loharia JJ, Alam JM, Abdelhadi HA, Marei TF.

Neurosciences (Riyadh). 2015 Jan;20(1):55-60.

4.

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA; American Heart Association Stroke Council.; Council on Cardiovascular and Stroke Nursing.; Council on Clinical Cardiology.; Council on Functional Genomics and Translational Biology.; Council on Hypertension..

Stroke. 2014 Dec;45(12):3754-832. doi: 10.1161/STR.0000000000000046.

5.

Relation of antiphospholipid antibodies to postmortem brain infarcts in older people.

Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Capuano AW, Yu L, Leurgans SE, Bennett DA, Levine SR.

Circulation. 2015 Jan 13;131(2):182-9. doi: 10.1161/CIRCULATIONAHA.114.012479.

6.

Sex differences in stroke: the contribution of coagulation.

Roy-O'Reilly M, McCullough LD.

Exp Neurol. 2014 Sep;259:16-27. doi: 10.1016/j.expneurol.2014.02.011. Review.

7.

Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study.

Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Leurgans SE, Yu L, Buchman AS, Arfanakis K, Fleischman DA, Boyle PA, Bennett DA, Levine SR.

Neuroepidemiology. 2013;40(2):73-84. doi: 10.1159/000342761.

8.

Epidemiology and etiology of young stroke.

Griffiths D, Sturm J.

Stroke Res Treat. 2011;2011:209370. doi: 10.4061/2011/209370.

9.

Treatment of risk factors to prevent stroke.

Aoki J, Uchino K.

Neurotherapeutics. 2011 Jul;8(3):463-74. doi: 10.1007/s13311-011-0054-0.

10.

Antiphospholipid syndrome and the brain in pediatric and adult patients.

Muscal E, Brey RL.

Lupus. 2010 Apr;19(4):406-11. doi: 10.1177/0961203309360808. Review.

11.

Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort.

Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Levine JS, Fortin PR.

Thromb Haemost. 2009 Jan;101(1):100-7.

12.

The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack.

Jensen MB, Chacon MR, Sattin JA, Aleu A, Lyden PD.

Neurologist. 2008 Jul;14(4):243-6. doi: 10.1097/NRL.0b013e31815a9945. Review.

Items per page

Supplemental Content

Support Center